



Jumping Genes-“*The Other Half of the Human Genome*” and the Missing Heritability Conundrum of Human Genetic Disorders

Deepu Pandita^{1*} and Anu Pandita^{2,3}

¹Government Education Department, Jammu, Jammu and Kashmir, India.

²Bee Enn College of Nursing, Talab Tillo, Jammu, Jammu and Kashmir, India.

³Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Authors' contributions

The manuscript was prepared by authors DP and AP. Both authors have read and approved the final manuscript.

Article Information

DOI: 10.9734/BBJ/2016/13904

Editor(s):

(1) Ghousia Begum, Toxicology Unit, Biology Division, Indian Institute of Chemical Technology, Hyderabad, India.

(2) Chung-Jen Chiang, Department of medical laboratory Science and Biotechnology, China Medical University, Taiwan.

(3) Kuo-Kau Lee, Department of Aquaculture, National Taiwan Ocean University, Taiwan.

Reviewers:

(1) Anonymous, University of Belgrade, Belgrade, Serbia.

(2) Mariluce Riegel, Federal University of Rio Grande do Sul, Brazil.

(3) Heui-Soo Kim, Pusan National University, South Korea.

(4) Tokunbo Yerokun, Spelman College, Atlanta, USA.

Complete Peer review History: <http://sciencedomain.org/review-history/12908>

Review Article

Received 9th September 2014

Accepted 19th December 2015

Published 6th January 2016

ABSTRACT

Almost 45% of the human genome is composed of transposons with about 4 million copies. The retrotransposons constitute 42% of the human genome with active families (Long Interspersed Nuclear Element, SINE-R, VNTR, and Alu) allied with insertional mutagenesis and diseases. There are >500,000 L1 copies which represent ~17% with less than 100 active copies and are inserted in the human genome; >1 million *Alu* copies referred to as “a parasite’s parasite” and ~3,000 SVA (SINE-R, VNTR, and Alu) copies. Some Human Endogenous Retroviruses are still active in humans. Nonactive DNA transposons embody 3% of the human genome. TEs are known to engender genomic instability and reorganize gene expression system in germline as well as the somatic cells. The amended retrotransposon expression or function appears to be associated with stress, alcohol, neurodegeneration and aging. This review highlights recent findings on the role of jumping genes in human genetic disorders like cancer, autoimmune and neurological diseases.

*Corresponding author: Email: deepupandita@gmail.com;

Keywords: TE: Transposable elements; human genome; human genetic diseases; long interspersed nuclear element; human endogenous retrovirus; SVA: SINE-R; VNTR; Alu.

1. INTRODUCTION

Transposons play a vital role in evolution and 45% of our genome encompasses transposable elements [1] (Fig. 1). Human transposons can be categorized as RNA transposons (retrotransposons) and DNA transposons. Retrotransposons which move by the process of retrotransposition (copy-and-paste mechanism) can be further subdivided into LTR (Long Terminal Repeat) (e.g; HERVs (Human Endogenous Retroviruses) and non-LTR transposable elements (e.g; LINEs (Long Interspersed Elements), SINES (Short Interspersed Elements), *Alus* (*Arthrobacter luteus*) and SVAs) while the DNA transposons mobilize by a cut-and-paste mechanism. The LINE-1 (L1), *Alu* and SVA which are explicitly active non-LTR retrotransposons, reciprocally make up about one third of the human genome (Fig. 2a) [2,3] and there are more than 60 reported cases of *de novo* insertions responsible for human genetic disorders [4-8]. For 80 to 100 latently active L1 in any individual, 101 *de novo* disease-causing germline retrotransposon insertions have been differentiated [6]. *De novo* insertions of L1 and SVA elements emerge respectively at the rate of roughly 1 in 108 births and 1 in 916 births [9], [10]. Approximately, 65 syndrome-based mutations in humans have been accredited to L1-mediated retrotransposition proceedings [11]. The most active *Alu* elements, account for 1 *de novo* germline insertion per 20 births [12]. L1 elements solitary encode which specially identify L1 mRNA molecules and the L1 machinery is co-opt by *Alu* and SVA elements. Endogenous retroviruses (ERVs) and ERV-like sequences comprise 8% of the human genome at 700,000 different loci [13]. About 40,000 HERV elements with truncated and solitary long terminal repeats have been identified. Almost 22 families of human ERVs are identified with one equipped of forming entire virus. ERVs may penetrate the genome via infection or through replication of accessible elements and shuffle DNA, add new promoters and new genes but also lead to various disease formations [14]. Diverse families of human endogenous retroviruses (HERVs) are present including HERV-E (30 to 50 copies per genome), HERV-R (1 copy per genome), HERV-H (50-100 with a provirus structure, thousands with a transposon structure), HERV-I (2-25 copies per genome), HERV-P (10-20 copies per

genome), and HERV-K (20-50 copies per genome). Some ERVs may still be active in humans' enzymes which are obligatory for retrotransposition [15], although the vast majority is nonfunctional. The expression of ERV sequences has been allied with a number of human diseases, such as multifactorial etiology or dysregulated immune functions, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, schizophrenia, cancer, cell tumours, melanoma and hematological disorders germ [13,16] but that expression as cause or effect of these diseases is not elucidated yet [16].

Brain often displays a surprising level of somatic mosaicism as compared to the rest of the body. Somatic mosaicism means the presence of two or more populations of cells with different genotypes in one individual who has developed from a single fertilized egg [17]. Somatic retrotransposition is linked to neurobiological genes. Severe mosaicism as chromosomal malformations can be a cancer sign; considerable mosaicism in a single gene across tissue types can be pinpointing to genetic diseases like the polyQ (polyglutamine) diseases; and moderate mosaicism is normal and to be expected [18,19]. Some transpositionally active LINE-1 retrotransposons contribute to brain mosaicism predominantly within the hippocampus, which produces neurons throughout [2]. LINE-1 retrotransposons are active and itinerant during neurogenesis in humans [20-22]. The recognition of somatic mobilization of active retrotransposons like LINEs, *Alus*' and SVA in varied human brain regions [3] advocates' role of active mobilization of transposons in normal brain development and budding substantiation implies alliance of unregulated transposon activation with neuropathology. The neuronal mosaicism due to L1 activity is apparent all over embryo development and in the adult brain [23], which is causative of genomic neuronal diversity athwart neurons of same individual leading to the phenomenon of the "one human, multiple genomes" [24]. That neuronal somatic mosaicism caused by retrotransposons [25] has broad repercussions in vast subject of neuroscience [2], [21,26]. The activation of transposons in human brain has been experiential in macular degeneration [27], FXTAS-Fragile-X associated tremor/ataxia syndrome [28], aging [29],

neurodegenerative diseases [30], alcoholism [31], ALS [32], Rett syndrome [33], Prion diseases [34,35], neurogenesis [20,21,33] and PTSD- post- traumatic stress disorder [36]. The macular degeneration and FXTAS may be attributable to activation of SINEs and LTR-retrotransposon [27,28]. According to Li et al. [30], TDP-43 broadly targets TE-derived transcripts of SINE, LINE, LTR and some DNA transposable elements. The compromise of TDP-43 protein function leads to over-expressed TEs causing genome instability and accumulation of TE-derived RNAs or proteins causes activation of DNA-damage stress response or toxic effects. This toxicity may contribute to TDP-43-mediated neurodegenerative disorders. Higher levels of L1 correlate with the occurrence of brain disorders, including Rett syndrome, major depression and Louis-Bar syndrome. Bundo et al. [37] while examining the brain tissue of deceased schizophrenia patients, found a 1.1-fold enhancement in L1, than in healthy controls. Baillie et al. [2] reported a somatic retrotransposition event in the intron of a histone deacetylase *Hdac1*- a known regulator of L1 expression within the human genome, suggesting how a single transposition event might alter the capacity of a given cell to regulate further insertions [38]. Retrotransposition may create target-site duplications (TSD)-microsatellites within the genome at the insertion points and trinucleotide repeats are indicative of a number of ailments, essentially of the central nervous system. The “polyQ disorders” known as “polyQ” because “Q” is the symbol for the amino acid, glutamine, which is coded by the sequence

“CAG are due to CAG repeat expansion within coding regions of certain genes, resulting in protein product with an expanded glutamine tract. The polyQ Disorders have reported somatic mosaicism within the mutated genes, such that different extremes of expansion are seen in different organ systems and include: spinal and bulbar muscular atrophy (SBMA), Huntington’s disease (HD), dentato rubral pallido luisian atrophy (DRPLA),and spinocerebellar ataxias (SCA) type 1, 2, 3, 7, and 17. The polyQ tracts may also form cytotoxic neuronal intranuclear inclusions (NII) [39]. For the CAG repeat disorders, the brain exhibits comparatively greater expansion than other tissues, with the notable exception of SBMA with greater variability in cardiac and skeletal muscle, skin, and prostate [40].

According to Kazazian et al. [4], Hemophilia A was due to *de novo* TE insertion which was one of the first studies to reveal that a TE insertion in human genome cause disease wherein an examination of 240 unrelated hemophilia A male patients showed that autonomous L1 mutagenic insertions into exon 14 of the *Factor VIII* gene caused this disease in two persons. The insertions of 3.8 and 2.3 kilobases contained 3’ portions of the L1 sequence, along with the poly (A) tract, which create TSDs (Target Site Duplications) of at least 12 and 13 nucleotides of the factor VIII gene and their 3’-trailer sequences following ORF-2 are almost indistinguishable from the consensus sequence of L1 cDNAs leading to confirmation of this disease by insertional mutation [4]. Similarly, 21 patients of




Fig. 1. The transposable element content of the human genome

About 45% of the human genome is composed of transposable elements, the vast majority of which are non-LTR retrotransposons (L1, Alu and SVA elements)




Fig. 2. Structure of active human retrotransposons

Autonomous elements encode the factors for their own mobilization. L1 ORF1 encodes RNA binding protein and ORF2 encodes a protein with endonuclease & reverse transcriptase roles. Human ERVs contain GAG, POL, and ENV genes. ERVs are flanked by LTRs (triangles) of 300–1,200 nucleotides. Alu and SVA are nonautonomous, relying on the L1-encoded retrotransposition machinery

Jewish ancestry suffering from retinitis pigmentosa was reported with having *Alu* insertion into an exon of the *MAK* (male germ-cell-associated kinase) gene [41] and Duchenne muscular dystrophy in a Japanese boy was identified due to L1-mediated orphan 3' transduction into the *dystrophin* gene [25].

Epigenetic and post-transcriptional suppression obstruct somatic cell retro transposition [38,42], excluding early embryo development [43] and some malignancies [38,43]. On the compromise of DNA methylation-mediated suppression system, HERVs and LTRs can cause detrimental and/or self-protecting effects. CSF1R oncogene activation by a MaLR LTR in Hodgkin's lymphoma and RCC-specific novel HERV-E antigen expression was reported. Methylation of HERV-W sequences was lost in the tumor DNA, symptomatic of interrelated DNA methylation and HERV-W expression in tumor milieu [44]. Human tumors having novel L1 retrotransposition events furthermore, displayed global patterns of hypomethylation, affording a correlative linkage between epigenetic changes and augmented L1 retrotransposition in tumors. Hypomethylation of L1 5' UTR has been experiential in malignant and cancer tissue, and is associated with

amplification in L1 mRNA and/or ORF1p expression [45].

The role of transposable elements in some of the human diseases is discussed briefly below.

1.1 Cancer

It is being hypothesized that the transposition of HERVs and other TEs in somatic cells, may insert in tumour suppressor genes which could lay foundation of neoplastic transformation. According to Tost J. [46], several cancers mark comprehensive DNA hypomethylation and local hypermethylation of CpG islands of tumour suppressor genes. Attributable to global DNA hypomethylation, the TEs transpose and may insert in or near the promoter region of tumour suppressor genes thus impeding their function and initiates neoplastic transformation on account of alteration in the cell cycle, blocking apoptosis or blocking DNA repair [46] followed by CpG island hypermethylation of promoters of genes inhibiting cell invasion and dissemination [47]. LTR of a MaLR human endogenous retrovirus leads to aberrant activation of a proto-oncogene, thereby causing lymphoma [34]. Hypomethylation of the HERV-K locus results in

increased HERV-K (22q11.23) expression in prostate and ovarian cancers [48,49] while hypomethylation of CpG dinucleotides within the promoter region results in HERV-W expression in ovarian cancer [50] and HERV-H (Xp22.3) expression in colon, gastric, and pancreatic cancers [51]. Hypomethylation of the U3 region of several HERV-W loci may lead to HERV-W activation in testicular cancer [52]. The HERV-K provirus family causes several cancers, because its members have open reading frames (ORFs) for all their viral genes. An endogenous retroviral envelope protein 'syncytin' has a role in placental trophoblast cell fusion, breast cancer-endothelial cell and endometrial carcinoma cell fusions [53]. LINE-1 transposons involve the *myc* gene in breast carcinoma and L1 insertion into the *adenomatous polyposis coli* (*APC*) gene in a colorectal tumor [53,54].

The identification of numerous non-germline *de novo* insertions in various kinds of cancers like lung cancer [55,56], brain cancer [57], glioblastoma [58,59], ovarian cancer [58,59], colorectal cancer [54,56,57], prostate cancer [57], multiple myeloma [57], hepatocarcinoma, breast cancer [56], and acute myeloid leukemia [56] was performed with high-throughput sequencing. Primary melanomas and testicular germ-cell cancers are extensively studied with evidence of HERVs in their tumorigenesis. HERV-K (HML-2) transforms melanocytes to melanomas while HERV-K ENV and GAG proteins preferentially express in primary melanoma cells and melanoma cell lines except benign melanocytic tumors. HERV-K also express in lymphoid metastases originating from primary tumors [60,61]. Testicular germ cell cancers caused by HERVs wherein Testicular germ cell tumors (GCT) arise from a dysfunction in spermatogenesis and HERV-K (HTL- 2) produce viral-like particles [62] with HERV-K transcripts and proteins in GCT cells [63]. Further in GCT patients, a specific immune response against HERV-K proteins is found [64]. HERV-K (HTL-2) Rec and Np9 proteins interact with PLZF and avoid accurate functioning of PLZF in the host and obstruct sperm cell maturation [65], while in normal cell, PLZF interrelates with proto-oncogene *c-myc*, inhibits its transcription, and proceeds as a spermatogenic stem cell regulator. By Rec and Np9 inhibition of PLZF, *c-myc* expression elevates and spermatogenic stem cells become unbalanced [66] while Np9 causes genetic instability in germ cells due to intervention with the Numb/Notch pathway [66,67] confirming their roles in tumorigenesis.

1.2 Autoimmune Diseases

Three mechanisms molecular mimicry, superantigen production, and LTR-mediated alterations of gene expression have been proposed for HERV-related pathology of autoimmune diseases.

1.2.1 Rheumatoid arthritis

Expression of multiple ERVs was detected in RA patients and that of HERV-K10 in juvenile RA. In juvenile rheumatoid arthritis patients HERV-K10 expression was up-regulated possibly because of Super-Antigen Stimulation in auto-reactive T cells causing autoimmunity [68,69]. The GAG and ENV proteins of HERV-K10 share the peptide sequences with the rheumatoid factor epitopes on IgG1Fc, entailing molecular mimicry [70]. HERV-K10, HERV-W (MSRV) and ERV-9 showed expression in normal and diseased synovium [68]. Friemanis et al. [70] using Quantitative RT-PCR and ELISA showed higher levels of HERV-K10 GAG activity in RA patients than controls. The prevalence of HERV-K113 exhibit increased levels in patients with SLE and RA [71] suggesting a role of HERVs in disease pathogenesis. According to Nelson et al. [72] there is noteworthy alliance of sequence homology between HERV-K10 and rheumatic arthritis. Reynier et al. [73] noticed higher levels of HERV-K10 in plasma of RA patients with NASBA and Ejtehadi et al. [74] observed Enhanced expression of HERV-K10 in RA with Multiplex RT-PCR.

1.2.2 Systemic lupus erythematosus

HERV-K ENV protein causes autoimmunity via molecular mimicry and immunomodulation. In this disorder the determinant shared by the host and the HERV-K ENV protein induces immune response and tissue destruction [71]. Banki et al. [75] using the Western blot and ELISA showed increased HRES-1 peptide binding activity in sera of patients than controls while Perl et al. [76] showed autoantibodies to HRES-1 in this disease. The HRES-1 (Human T-cell lymphotropic virus-related Endogenous Sequence) locus at the 1q42 chromosomal region controls SLE development and expressions [77]. Deas et al. [78] illustrated that the cells exposed to HIAP-1 may be guarded from apoptosis. Talal et al. [79,80] exhibited presence of antibodies to p24 GAG of HIV-1 in nonexistence of HIV-1 infection and anti-Sm antibodies can cross-react with p24 GAG.

Hypomethylation of HERV-E and HERV-K was observed in SLE patients [81,82].

1.2.3 Sjögren's syndrome

The cells exposed to salivary tissue from patients with Sjögren's syndrome showed presence of HIAP-1 [83]. Considerably higher levels of antibodies to HTLV-1 [84] and Anti-p30 GAG antibodies (HERV-E ENV protein) were perceived in sera of several diseases [85].

1.2.4 Insulin dependent diabetes mellitus

Immunemediated (Type 1) diabetes is a multigenetic and autoimmune disease [86]. HERV-K18 which encodes for a T-cell superantigen (SAG) is involved in the etiology of type 1 diabetes. T-cells with T-cell receptor V β 7 chains reactive to the SAG and HERV-K18 mRNA were enriched in the pancreas, spleen [87,88] and in circulation [89] at the onset of the disease. HERV-K18 transcription and SAG function in cells (induced by proinflammatory stimuli) trigger progression of disease to insulinitis or from insulinitis to overt diabetes [90,91]. HERV-K (C4) is a novel marker of Type 1 diabetes and individuals with Type 1 diabetes have appreciably lower HERV-K (C4) copies [92]. According to Conrad B. [93], HERV-K ENV encodes a super-antigen responsible for the etiology of insulin-dependent *Diabetes mellitus*.

1.2.5 Psoriasis

The retroviruses were suggested to have a role in psoriasis [94] and retroviral like proteins were found in urine, skin and lymphocytes of psoriasis patients [95]. Expression of HERV-W, HERV-K, and HERV-E and a newly identified ERV-9/HERV-W variant in psoriasis development was reported by Moles J. P. et al. [96].

1.2.6 Multiple sclerosis

HERV-W family has a physiological role in multiple sclerosis as a cofactor and predictor of disease progression [97]. Multiple Sclerosis Associated Retroviral element have been correlated with the evolution and prognosis of Multiple sclerosis, wherein HERV-W ENV gene codes for an envelope protein called syncytin-1 [98], which distinct from its positive role in placenta morphogenesis, operates as a potent immuno-pathogenic molecule that prompts a pro-inflammatory and autoimmune cascade. There is a strong linkage between the MS-associated retroviral element (MSRV)-type HERV-W and MS wherein the ENV RNA and

protein expression considerably increases in the blood and brain cells, HERV-H/F family HERV-Fc1 expression in T lymphocytes and the plasma HERV-Fc1 RNA level also boosts in patients with MS. HERV-K18 (chromosome 1) was initiated to be a risk factor of MS and other human autoimmune disorders [99-103]. The Immune tolerance of HERV-W Env (Syncytin-1), GAG and other HERV-W proteins would avert the production of an immune response against HERV-W/MSRV antigens that initiate MS owing to altered or ectopic expression [104].

1.3 Neurological Diseases

1.3.1 Schizophrenia

Schizophrenia and brain-related genes likely house higher-than-average transposable elements, causing relative instability, enhanced insertion and recombination rates. The negligible TE insertions lead to mutations in schizophrenia-related genes [37], while the enhanced rates of "successful" TE insertions are still active in the human genome. The neurons taken from schizophrenic patients postmortem showed higher numbers of L1 retrotransposons than glial cells within the same brains, liver tissue from same patient in comparison to control brain and liver tissues i.e.; individual neurons from schizophrenics showed higher levels of L1-induced somatic mosaicism and the L1 insertions tended to preference synaptic, cytoskeletal and cell adhesion genes of central nervous system-related genes in schizophrenics. Bundo et al. [37] reported an increase in copy number of LINE1 in postmortem tissues and induced pluripotent stem cells (iPSC) from schizophrenic patients diagnosed with 22q11-deletion syndrome. The most cases of 22q11 deletion syndrome likely stem from *Alu*-mediated recombination, not from L1 insertion [68]. According to Bundo et al. [37] hyperactive retrotransposition of L1 in neurons elicited by milieu and/or genetic factors may add to the vulnerability and pathophysiology of schizophrenia. Gottipati et al. [39] suggests that the gene-associated forms of schizophrenia and autism may be because of a variety of recombinatory and transposition events arising from gene destabilization such as occur during transcription. Muotri et al. [21], reported substantially increased L1 retrotransposition in neural progenitors during early stages of differentiation. In the late 1950's and early 1960's, a study on the blood samples from pregnant women showed that antibody to HSV-2 correlated with offspring development of

schizophrenia [105]. It in conjunction with the proof of HERV protein expression in the brains of patients, demonstrates that attacking pathogens may have the prospective to transactivate HERV sequences causing elevated disease sternness [106,107]. Rees et al. [108], reported that, in contrast to copy number variant deletions at the genetic locus, 22q11, which increase schizophrenia risk, duplications in the same region appear to be linked with greater protection against the condition. Bundo et al. [37] study has highlighted the potential importance of genetic instability in schizophrenia's etiology. However, while some gene mutations may arise due to retrotransposon insertion, this is probably only one of a number of destabilizing events that target schizophrenia-risk genes. Karlsson et al. [109] established that RNA transcripts homologous to HERV-W family members are upregulated to different levels in the frontal cortex obtained from post-mortem schizophrenic patients than RNA in the plasma of patients with recent-onset schizophrenia [110].

Yolken et al. [111] reported the up regulation of HERV-W and HERV-K transcription and Frank et al. [112] reported over-expression of HERV-K in the cortex of post-mortem brains of SCZ and BD versus Healthy Controls. Weis et al. [113] reported reduced expression of HERV-W GAG in neurons and astroglial cells in SCZ, BP and MDD versus Healthy Controls while Lin et al. [114] reported more frequent HERV-K115 insertion in patients with younger onset of schizophrenia than those with later onset. According to Dickerson et al. [115] two-polymorphism haplotype in the envelope region of HERV K-18, located in the CD48 SLAM- signaling lymphocyte activating gene on chr1, is highly associated with type 2 diabetes in a population of 229 individuals with SCZ versus 136 Healthy Controls. Perron et al. [116] reported significantly higher antigenemia of HERV-W ENV and GAG proteins in individuals with SCZ versus Healthy Controls; and significant correlation of antigenemia with C-reactive protein (CRP).

Yao et al. [117] reported higher prevalence of HERV-W GAG transcripts in SCZ versus HC and higher rate transcription of intronic elements on the noncoding strand of PTD015 (11q13.5) in the patients during the transition from susceptibility to manifestation of symptoms. Huang et al. [118] showed higher prevalence of HERV-W ENV transcripts in SCZ versus HC and over-expression of HERV-W upregulate BDNF, NTRK2, DRD3 and increase CREB protein.

Further, significant increase in HERV-W ENV transcription in BD and in SZ versus Healthy Controls was reported and the corresponding DNA copy number was paradoxically lower in the genome of patients with BD or SZ than in Healthy Controls [119,120]. Abrusan [121] reported the effect of somatic retrotransposition on brain metabolism and biosynthesis of 250 metabolites, together with dopamine, serotonin and glutamate in Schizophrenia and Parkinson's disorders.

1.3.2 Autism

Autism-related genes house large TE content. The DNA fragments which house numerous TEs attract extra TEs over evolution. The genes with TE in intronic regions usually have all types of transposable elements therein, suggesting that coding regions may have a hard time accommodating TE insertion ultimately selecting against it and that introns attract TE insertion. The more TEs, the more TEs they attract over the epochs and the greater the TE content, the more unstable that region is overall. Some of the largest genes in the human genome known for high rates of mutation, several of them also high-risk autism genes like *CNTNAP2* and *DMD*, which house thousands of intronic transposable elements. These results suggest a relationship between transposable element content and autism-risk genes and have implications for the stability of those genomic regions" [122]. In a similar study [11,123] reported higher percentages of transcripts from subfamilies of LTR retroelements in cases of autism in contrast to controls and HERV-H over-expression in ASD versus Healthy Controls and HERV-W down-expression in ASD versus Healthy Controls.

1.3.3 Attention Deficit Hyperactivity Disorder (ADHD)

Attention deficit hyperactivity Disorder (ADHD) is a neurodevelopmental disorder occurring because of complex interaction of environmental, biological and genetic factors. The expression of retroviral mRNAs from the three HERV families (HERV-H, K and W) was evaluated in peripheral blood mononuclear cells (PBMCs) from ADHD patients. The expression levels of HERV-H were notably elevated in ADHD patients in comparative to healthy controls suggesting a role of HERVs in the neurodevelopment diseases, while HERV-K and W showed no difference in expression [123].

1.3.4 Bipolar disorder

Yolken et al. [111] reported the up regulation of HERV-W and HERV-K transcription in the cortex of postmortem brains of SCZ and BD versus Healthy Controls [112]. According to Perron et al. [116] there is drastically higher HERV-W ENV transcription in BD and in SZ versus Healthy Controls. The analogous DNA copy number was ironically lesser in the genome of patients with BD or SZ than in Healthy Controls. Weis et al. [113] reported reduced expression of HERV-W GAG in neurons and astroglial cells in SCZ, BD and MDD versus Healthy Controls in post-mortem brain tissue.

1.3.5 Major depression

Weis et al. [113] reported reduced expression of HERV-W GAG in neurons and astroglial cells in SCZ, BD and MDD versus Healthy Controls in post-mortem brain tissue.

1.3.6 Post-traumatic stress disorder

Rusiecki et al. [124] reported DNA methylation evaluated via pyrosequencing in pre- and post deployment serum that the LINEs were hypermethylated in controls post- versus predeployment, hypomethylated in cases versus controls post deployment. *Alus* were hypermethylated for cases versus controls pre deployment. According to Ponomarev et al. [36], genome-wide gene expression profile in amygdala leads to identification of a module of stress regulated highly co-expressed transcripts with no annotations mapping to genomic locations corresponding to LINE-1.

1.3.7 Alcohol dependence

Post-mortem brain from central and basolateral nucleus of amygdala, plus the superior frontal cortex illustrated co-expressed SINE and LTR up-regulated in the central and basolateral amygdala and superior frontal cortex of the alcoholic brain; and regions similar to upregulated probes corresponding to a currently "active" LINE-1 family, L1HS show increased hypomethylation in alcoholics [22]. The stress and/or chronic alcohol may lead to TE transcriptional activation. Chronic alcohol abuse resulted in DNA hypomethylation and transcriptional activation of LTR-containing transposons LINE-1 TE [31].

1.3.8 Ataxia telangiectasia

Ataxia telangiectasia is an autosomal recessive disorder leading to progressive neurological

degeneration, immune deficiency, lymphoreticular malignancies, chromosomal instability, growth retardation, gonadal dysgenesis, telangiectases and premature aging of skin and hair with a frequency of 1:40,000–100,000 live births worldwide. In this neurodegenerative disorder, enhanced retro transposition activity in L1 cells with lack of ATM and enhanced copy number of L1HS in Ataxia telangiectasia patients versus Healthy Controls was reported in L1RP–EGFP post-mortem tissue of human brain [125].

1.3.8.1 Infantile encephalopathy

In post-mortem brain tissue [126] point mutation in intron of SLC7A2 in a primate-specific retrotransposon sequence and related enhancement of neuronal apoptosis in vitro KO for this transcript were reported.

1.3.8.2 Frontotemporal Lobar Degeneration (FTLD)

The cross linking immunoprecipitation sequencing data, RNA immuno-precipitation sequencing data, CLIP-seq and mRNA-seq datasets of human and mouse, Li et al. [29,30] reported that TDP-43 broadly targets TE-derived transcripts, including many SINEs, LINEs, LTR retroelements plus some DNA elements and the association between TDP-43 and TE-derived RNA targets lessens in FTLD patients relative to healthy subjects and over-expression of TE derived transcripts in each of two different mouse models with TDP-43 dysfunction in this neurodegenerative disorder.

1.3.8.3 Di George syndrome

DiGeorge syndrome is the most recurrent contiguous-human gene deletion syndrome having an incidence of 1 in 4,000 live births [127]. In this mental retardation, *Alu*-mediated chromosomal rearrangements leading to micro deletions on 22q11 were reported [97].

1.3.8.4 Motor neuron disease

Motor neuron disease which is a clinical syndrome is mainly caused by the mutation of superoxide dismutase 1 (SOD1) gene. This gene is modulated by the HERV W ENV protein synctin in the placenta wherein its expression is elevated [109]. The elevated expression of HERV-W ENV and GAG genes have been detected and proposed in this pathogenesis [36].

Table 1. Some other human disorders where transposons cause insertional mutagenesis and recombination in genes

Transposons involved	Copy number	Gene	Disorders reported in humans	Element	References
SINES	1 million	NF1	Neurofibromatosis type1	<i>Alu Ya5</i>	[128-130]
Alu		<i>FGFR2</i>	Apert Syndrome	<i>Alu Ya5</i>	[128-129]
		BCHE	Acholinesterasemia	<i>Alu Yb8</i>	[131]
		Factor IX	Hemophilia B	<i>Alu Ya5, Yb8</i>	[128-129]
		Factor VIII	Hemophilia A X-linked Severe Bleeding Disorder	<i>Alu Yb8, Yb9</i>	[128-129]
		CASR	Familial Hypocalciuric Hypercalemia and hyperparathyroidism	<i>Alu Ya4</i>	[128-129]
		ADD1	Huntington Disease	<i>Alu</i>	[132]
		GK	Glycerol Kinase Deficiency	<i>Yc1</i>	[128-129]
		CTDP1	CCFDN Syndrome	<i>YF4</i>	[133]
		Fas	Autoimmune Lympho Proliferative Syndrome	<i>Sb1</i>	[128-129]
		CLCN5	Dent's Disease	<i>Ya6, Ya5</i>	[128-129]
		BTK	X-Linked Agammaglobulinemia	<i>Y, Y</i>	[128-129]
		IL2RG	X-linked severe combined immunodeficiency disease	<i>Ya5</i>	[128-129]
		CD40LG	Hyper IgM syndrome	<i>Yb8</i>	[128-129]
		ATP7A	Menkes Disease	<i>Ya5a2</i>	[128-129]
		CRB1	Retinitis Pigmentosa	<i>Y</i>	[128-129]
		ZFH1B	Mowat-Wilson Syndrome	<i>Ya5</i>	[128-129]
		BCHE	Cholinesterase Deficiency	<i>Yb8</i>	[128-129]
		MLV12	Associated with leukemia	<i>Ya5</i>	[128-129]
		APC	Hereditary Desmoid Disease	<i>Yb8</i>	[128-129]
		P5N1	Chronic Hemolytic Anemia	<i>Ya5</i>	[128-129]
		EYA1	Branchio-oto-renal Syndrome	<i>Y</i>	[128-129]
		LPL	Lipoprotein Lipase Deficiency	<i>Yb9</i>	[128-129]
		POMT1	Walker Warburg Syndrome	<i>Ya5</i>	[128-129]
		TNFRSF6	Autoimmune Lymphoproliferative Syndrome	<i>Yb8</i>	[128-129]
		C1NH	Complement Deficiency	<i>Yc1</i>	[128-129]
		AIP	Acute Intermittent Porphyria	<i>Ya5</i>	[128-129]
		BRCA1	Breast Cancer	<i>Ya5</i>	[128-129]
		GNPTAB	Mucopolidosis	<i>Y</i>	[134]
		BRCA2	Breast Cancer	<i>Ya5, Yc1, Y</i>	[135]
		PMM2	Congenital Disorder of Glycosylation Type I	<i>Yb8</i>	[136]
		CHD7	Charge Syndrome		[137]

Transposons involved	Copy number	Gene	Disorders reported in humans	Element	References		
LINES L1	500000	ZEB2	Muckle–Wells Syndrome		[138]		
		Factor VIII	Hemophilia A	L1	[138]		
		APC	FAP	L1	[139]		
		Dystrophin	Muscular Dystrophy	L1	[140]		
		Globin (HBB)	Beta Thalassemia	L1	[138]		
		RP2	X-linked Retinitis Pigmentosis	L1	[138]		
		DMD	X-linked Duchenne Muscular Dystrophy	L1	[138][141]		
		Fukutin	Cyctic Fibrosis	L1	[142]		
		Factor IX	Hemophilia B	L1	[138]		
		CHM	Choroideremia	L1	[138]		
		CYBB	Chronic Granulomatous Disease	L1	[138]		
		RPS6KA3	Coffin–Lowry syndrome	L1	[138]		
		APC	Colon Cancer	L1	[138]		
		FKTN	Fukuyama-type Congenital Muscular Dystrophy	L1	[138]		
		PDHX	Pyruvate Dehydrogenase Complex Deficiency	L1	[143]		
		SVA	~3,000	Fukutin-FKTN	Fukuyama-type Congenital Muscular Dystrophy		[138]
				BTK	X-linked Agammaglobulinemia		[140][138]
LDLRAP	Autosomal Recessive Hypercholesterolemia				[138]		
HERVs	200000	SPTA	Hereditary Elliptocytosis and Hereditary Pyropoikilocytosis		[138]		
		AZFa (Azoospermia Factor A)	Male Infertility	HERV15	[144-145]		

Hsmar2 DNA transposons is related with hotspots for homologous recombination connected with human genetic disorders like Charcot–Marie–Tooth, Prader-Willi/Angelman, and Williams syndromes [17,146,147].

The other human diseases which are caused by various categories of transposons through insertional mutagenesis of retrotransposons and recombination in genes are listed in the Table 1.

2. CONCLUSION AND RECOMMENDATIONS

To conclude the transposon insertions can lead to various human genetic disorders and signify that there's a great deal to a genome than genes. Incidentally, medical therapeutics comprehending the core progressions of transposons producing human diseases could facilitate their forestalling and alleviation, like in multiple sclerosis a novel salutary approach involves targeting of the MSR-V-ENV (Human Endogenous Retroviral protein) with a copious humanized monoclonal antibody [5,148]. Again HERVs signatures linked with definite cancers, along with epigenetic signatures are promising bio-indicators which are being deciphered and data based as a means for assessing, cancer risk, premature cancer detection, treatment scrutinization and prediction in the future. This can be applicable to other human syndromes involving HERVs and epimutation signatures [129,130,18]. The somatic retrotransposition high frequency elucidates why such as homozygote twins may possibly have cacophonous conducts and/or syndrome effects, and can explicate the omitted heritability dilemma for several ailments including the psychiatric and neurological disorders. Markedly, the "JUNK" of yesterday is stepping into the glare of publicity and is proving as "Just Unrevealed New-fangled Know-how" of tomorrow hidden in our genomes which may be involved in some phenotypic variations and human-specific traits as well and holds the promise in personalized medicine.

ACKNOWLEDGEMENTS

One of the authors, DP acknowledges contribution of Prof. Manoj Kumar Dhar, Director, School of Biotechnology, University of Jammu, Jammu, India for inspiring DP to work on transposons during her research career. The Council of Scientific and Industrial Research (CSIR) New Delhi, India is acknowledged for funding.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

1. Cordaux R, Batzer MA. The impact of retrotransposons on human genome evolution. *Nature Reviews Genetics*. 2009;10(10):691-703.
2. Baillie J, Barnett M, Upton K, Gerhardt D, Richmond T, De SF, et al. Somatic retrotransposition alters the genetic landscape of the human brain. *Nature*. 2011;479(7374):534-537.
3. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. *Nature*. 2001;409:860-921.
4. Kazazian Jr, Wong C, Yousoufian H, Scott AF, Phillips DG, Antonarakis SE. Hemophilia a resulting from *de novo* insertion of L1 sequences represents a novel mechanism for mutation in man. *Nature*. 1988;332:164-166.
5. Deininger PL, Batzer MA. *Alu* repeats and human disease. *Molecular Genetics and Metabolism*. 1999;67:183-193.
6. Chen JM, Stenson PD, Cooper DN, Ferec C. A systematic analysis of LINE-1 endonuclease-dependent retrotranspositional events causing human genetic disease. *Human Genetics*. 2005;117:411-427.
7. Callinan PA, Batzer MA. Retrotransposable elements and human disease. *Genome Dynamics*. 2006;1:104-115.
8. Belancio VP, Hedges DJ, Deininger P. Mammalian non-LTR retrotransposons: For better or worse, in sickness and in health. *Genome Research*. 2008;18:343-358.
9. Huang CR, Schneider AM, Lu Y, Niranjan T, Shen P, Robinson MA, et al. Mobile interspersed repeats are major structural variants in the human genome. *Cell*. 2010;141:1171-1182.
10. Xing J, Zhang Y, Han K, Salem AH, Sen SK, Huuff CD, et al. Mobile elements create structural variation: Analysis of a complete human genome. *Genome Research*. 2009;19:1516-1526.
11. Balestrieri E, Arpino C, Matteucci C, Sorrentino R, Pica F, Alessandrelli R, et al. HERVs expression in autism spectrum disorders. *PLoS ONE*. 2012;7(11):e48831.

12. Cordaux R, Hedges DJ, Herke SW, Batzer MA. Estimating the retrotransposition rate of human *Alu* elements. *Gene*. 2006; 373:134-137.
13. Mayer J, Blomberg J, Seal RL. A revised nomenclature for transcribed human endogenous retroviral loci. *Mobile DNA*. 2011; 2:7.
14. Bromham L, Clark F, McKee JJ. Discovery of a novel murine type C retrovirus by data mining. *Journal of Virology*. 2001;75:3053-3057.
15. Moyes D, Griffiths DJ, Venables PJ. Insertional polymorphisms: A new lease of life for endogenous retroviruses in human disease. *Trends in Genetics*. 2007;23:326-333.
16. Griffiths JD. Endogenous retroviruses in the human genome sequence. *Genome Biology*. 2001;2(6):1017.1-1017.5.
17. Urban Z, Helms C, Fekete G, Csiszár K, Bonnet D, Munnich A, et al. 7q11.23 deletions in Williams syndrome arise as a consequence of unequal meiotic crossover. *American Journal of Human Genetics*. 1996;59:958-962.
18. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. *Proceedings of the National Academy of Sciences, USA*. 1994;91(21):9871-9875.
19. Harry TO. Beyond the Qs in the polyglutamine diseases. *Genes and Development*. 2001;15: 925-932.
20. Coufal NG, Garcia-Perez JL, Peng GE, Yeo GW, Mu Y, Michael T, et al. L1 retrotransposition in human neural progenitor cells. *Nature*. 2009;460:1127-1131.
21. Muotri AR, Chu VT, Marchetto MC, Deng W, Moran JV, GAGe FH. Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. *Nature*. 2005;435:903-910.
22. Muotri AR, Zhao C, Marchetto MC, GAGe FH. Environmental influence on L1 retrotransposons in the adult hippocampus. *Hippocampus*. 2009;19: 1002-1007.
23. Thomas CA, Paquola AC, Muotri AR. LINE-1 retrotransposition in the nervous system. *Annual Review of Cell and Developmental Biology*. 2012;28:555-573.
24. Lupski JR. Genetics. Genome mosaicism: One human, multiple genomes. *Science*. 2013;341:358 -359.
25. Singer T, McConnell MJ, Marchetto MC, Coufal NG, GAGe FH. LINE-1 retrotransposons: Mediators of somatic variation in neuronal genomes? *Trends in Neurosciences*. 2010;33:345-354.
26. Perrat PN, DasGupta S, Wang J, Theurkauf W, Weng Z, Rosbash M, et al. Transposition- driven genomic heterogeneity in the Drosophila brain. *Science*. 2013;340:91-95.
27. Kaneko H, Dridi S, Tarallo V, Gelfand BD, Fowler BJ, Cho WG, et al. DICER1 deficit induces *Alu* RNA toxicity in age-related macular degeneration. *Nature*. 2011;471:325-330.
28. Tan H, Qurashi A, Poidevin M, Nelson DL, Li H, Jin P. Retrotransposon activation contributes to fragile X premutation rCGG-mediated neurodegeneration. *Human Molecular Genetics*. 2012;21:57-65.
29. Li W, Prazak L, Chatterjee N, Grüninger S, Krug L, Theodorou D, et al. Activation of transposable elements during aging and neuronal decline in Drosophila. *Nature Neuroscience*. 2013;16:529-531.
30. Li W, Jin Y, Prazak L, Hammell M, Dubnau J. Transposable elements in TDP-43 mediated neurodegenerative disorders. *PLoS ONE*. 2012;7:9.
31. Ponomarev I, Wang S, Zhang L, Harris RA, Mayfield RD. Gene coexpression networks in human brain identify epigenetic modifications in alcohol dependence. *The Journal of Neuroscience*. 2012;32:1884-1897.
32. Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. *Annals of Neurology*. 2011;69:141-151.
33. Muotri AR, Marchetto MC, Coufal NG, Oefner R, Yeo G, Nakashima K, et al. L1 retrotransposition in neurons is modulated by MeCP2. *Nature*. 2010;468(7322):443-446.
34. Lathe R, Harris A. Differential display detects host nucleic acid motifs altered in scrapie-infected brain. *Journal of Molecular Biology*. 2009;392:813-822.
35. Stengel A, Roos C, Hunsmann G, Seifarth W, Leib-Mosch C, Greenwood AD. Expression profiles of endogenous retroviruses in old world monkeys. *Journal of Virology*. 2006;80:4415-4421.
36. Ponomarev I, Rau V, Eger EI, Harris RA, Faselow MS. Amygdala transcriptome and cellular mechanisms underlying

- stress-enhanced fear learning in a rat model of posttraumatic stress disorder. *Neuropsychopharmacology*. 2010;35:1402-1411.
37. Bundo M, Toyoshima M, Okada Y, Akamatsu W, Ueda J, Nemoto-Miyauchi Taeko, et al. Increased L1 retrotransposition in the neuronal genome in schizophrenia. *Neuron*. 2014;81(2):306-313.
38. Garcia-Perez JL, Morell M, Scheys JO, Kulpa DA, Morell S, Carter CC, et al. Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. *Nature*. 2010;466:769-773.
39. Gottipati P, Cassel TN, Savolainen L, Helleday T. Transcription-associated recombination is dependent on replication in mammalian cells. *Molecular and Cellular Biology*. 2008;28:154-164.
40. Wells RD, Ashizawa T. genetic instabilities and neurological diseases. Academic Press; 2006. ISBN-10: 0123694620, ISBN-13:978-0123694621, Edition: 2.
41. Strachan T, Read AP. "Glossary". Human molecular genetics (2nd Ed.). New York: Wiley-Liss; 1999. ISBN 1-85996-202-205.
42. Yang N, Kazazian HH Jr. L1 retrotransposition is suppressed by endogenously encoded small interfering RNAs in human cultured cells. *Nature Structural and Molecular Biology*. 2006; 13:763-771.
43. Kano H, Godoy I, Courtney C, Vetter MR, Gerton GL, Ostertag EM, et al. L1 retrotransposition occurs mainly in embryogenesis and creates somatic mosaicism. *Genes and Development*. 2009;23 (11):1303-1312.
44. Gimenez J, Montgiraud C, Pichon JP, Bonnaud B, Arzac M, Ruel K, et al. Custom human endogenous retroviruses dedicated microarray identifies self-induced HERV-W family elements reactivated in testicular cancer upon methylation control. *Nucleic Acids Research*. 2010;38:2229-2246.
45. Belancio VP, Roy-Engel AM, Deininger PL. All y'all need to know 'bout retroelements in cancer. *Seminars in Cancer Biology*. 2010;20:200-210.
46. Tost J. Epigenetics. Caister Academic Press; 2008.
47. Esterl M. DNA methylation, epigenetics and metastasis. Springer; 2005.
48. Goering W, Ribarska T, Schulz WA. Selective changes of retroelement expression in human prostate cancer. *Carcinogenesis*. 2011;32:1484-1492.
49. Iramaneerat K, Rattananunyong P, Khemapech N, Triratanachat S, Mutirangura A. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance. *International Journal of Gynecological Cancer*. 2011;21:51-57.
50. Menendez L, Benigno BB, McDonald JF. L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. *Molecular Cancer*. 2004;3:12.
51. Wentzensen N, Coy JF, Knaebel HP, Linnebacher M, Wilz B, Gebert J, et al. Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers. *International Journal of Cancer*. 2007;121:1417-1423.
52. Katoh I, Kurata S. Association of endogenous retroviruses and long terminal repeats with human disorders. *Frontiers in Oncology*. 2013;3:234.
53. Bjerregaard B, Holck S, Christensen IJ, Larsson LI. Syncytin is involved in breast cancer-endothelial cell fusions. *Cellular and Molecular Life Sciences*. 2006; 63:1906-1911.
54. Solyom S, Ewing AD, Rahrman E, Doucet T, Nelson H, Burns B, et al. Extensive somatic L1 retrotransposition in colorectal tumors. *Genome Research*. 2012;22: 2328-2338.
55. Iskow RC, McCabe MT, Mills RE, Torene S, Pittard WS, Neuwald AF, et al. Natural mutagenesis of human genomes by endogenous retrotransposons. *Cell*. 2010;141:1253-1261.
56. Ewing AD, Ballinger TJ, Earl D, Harris CC, Ding L, Wilson RK, et al. Retrotransposition of gene transcripts leads to structural variation in mammalian genomes. *Genome Biology*. 2013;14:R22.
57. Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ, et al. Cancer genome atlas research network: Landscape of somatic retrotransposition in human cancers. *Science*. 2012;337:967-971.
58. Wang-Johanning F, Liu J, Rycak K, Huang M, Tsai K, Rosen DG, et al. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian

- cancer. *International Journal of Cancer*. 2007;120:81-90.
59. Collins VP. Brain tumours: Classification and genes. *Journal of Neurology, Neurosurgery and Psychiatry*. 2004;75 (Suppl 2): ii2- ii11.
 60. Buscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. *Cancer Research*. 2005;65:4172-4180.
 61. Serafino A, Balestrieri E, Pierimarchi P, Matteucci C, Moroni G, Oricchio E, et al. The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. *Experimental Cell Research*. 2009;315: 849-862.
 62. Bronson DL, Fraley EE, Fogh J, Kalter SS. Induction of retrovirus particles in human testicular tumor (Tera-1) cell cultures: An electron microscopic study. *Journal of National Cancer Institute*. 1979;63:337-339.
 63. Ruprecht K, Ferreira H, Flockerzi A, Wahl S, Sauter M, Mayer J, et al. Human endogenous retrovirus family HERV-K (HML-2) RNA transcripts are selectively packaged into retroviral particles produced by the human germ cell tumor line Tera-1 and originate mainly from a provirus on chromosome 22q11.21. *Journal of Virology*. 2008;82:10008-100016.
 64. Kleiman AM, Seniuta NB, Triakin AA, Vinogradova TV, Karseladze AI, Souther M, et al. Expression of endogenous retroviruses of the HERV-K/HTDV family in patient with germinogenic tongue tumors. *Voprosy Virusologii*. 2001;46:15-21.
 65. Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N. Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. *Journal of Virology*. 2007;81:5607-5616.
 66. Ruprecht K, Mayer J, Sauter M, Roemer K, Mueller-Lantzsch N. Endogenous retroviruses and cancer. *Cellular and Molecular Life Science*. 2008;65:3366-3382.
 67. Armbruester V, Sauter M, Roemer K, Best B, Hahn S, Nty A, et al. Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X. *Journal of Virology*. 2004;78:10310-10339.
 68. Nakagawa K, Brusica V, McColl G, Harrison LC. Direct evidence for the expression of multiple endogenous retroviruses in the synovial compartment in rheumatoid arthritis. *Arthritis Rheumatology*. 1997; 40:627-638.
 69. Sicat J, Sutkowski N, Huber BT. Expression of human endogenous retrovirus HERV-K18 super antigen is elevated in juvenile rheumatoid arthritis. *Journal of Rheumatology*. 2005;32:1821-1831.
 70. Freimanis G, Hooley P, Ejtehadi HD, Ali HA, Veitch A, Rylance PB, et al. A role for human endogenous retrovirus-K (HML-2) in rheumatoid arthritis: Investigating mechanisms of pathogenesis. *Clinical and Experimental Immunology*. 2010;160:340-347.
 71. Krzyszczalowska-Wawrzyniak M, Ostanek M, Clark J, Binczak-Kuleta A, Ostanek L, Kaczmarczyk M, et al. The distribution of human endogenous retrovirus K-113 in health and autoimmune diseases in Poland. *Rheumatology*. 2011;50(7):1310-1314.
 72. Nelson PN, Lever AM, Smith S, Pitman R, Murray P, Perera SA, et al. Molecular investigations implicate human endogenous retroviruses as mediators of antiretroviral antibodies in autoimmune rheumatic disease. *Immunological Investigation*. 1999;28(4):277-289.
 73. Reynier F, Verjat T, Turrel F, Imbert PE, Marotte H, Mouglin B, et al. Increase in human endogenous retrovirus HERV-K (HML-2) viral load in active rheumatoid arthritis. *Scand. Journal of Immunology*. 2009;70:295-299.
 74. Ejtehadi HD, Freimanis GL, Ali HA, Bowman S, Alavi A, Axford J, et al. The potential role of human endogenous retrovirus K10 in the pathogenesis of rheumatoid arthritis: A preliminary study. *Annals of the Rheumatic Diseases*. 2006;65:612-616.
 75. Banki K, Maceda J, Hurley E, Ablonczy E, Mattson DH, Szegedy L, et al. Human T-cell lymphotropic virus (HTLV)-related endogenous sequence, HRES-1, encodes a 28-kDa protein: A possible autoantigen for HTLV-I GAG-reactive autoantibodies. *Proceedings of the National Academy of Sciences of the United States of America*. 1992;89:1939-1943.
 76. Perl A, Colombo E, Dai H, Agarwal R, Mark KA, Banki K, et al. Antibody reactivity to the HRES- 1 endogenous retroviral element identifies a subset of patients with

- systemic lupus erythematosus and overlap syndromes. Correlation with antinuclear antibodies and HLA class II alleles. *Arthritis and Rheumatism*. 1995;38(11): 1660-1671.
77. Pullmann R Jr., Bonilla E, Phillips PE, Middleton FA, Perl A. Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. *Arthritis and Rheumatism*. 2008;58:532-540.
78. Deas JE, Thompson JJ, Fermin CD, Liu, LL, Martin D, Garry RF, et al. Viral induction, transmission and apoptosis among cells infected by a human intracisternal A-type retrovirus. *Virus Research*. 1999;61(1):19-27.
79. Talal N, Dauphinee MJ, Dang H, Alexander SS, Hart DJ, Garry RF. Detection of serum antibodies to retroviral proteins in patients with primary Sjogren's syndrome (autoimmune exocrinopathy). *Arthritis Rheumatism*. 1990;33:774-781.
80. Talal N, Garry RF, Schur PH, Alexander S, Dauphinée MJ, Livas IH, et al. A conserved idiotype and antibodies to retroviral proteins in systemic lupus erythematosus. *The Journal of Clinical Investigation*. 1990;85:1866-1871.
81. Ogasawara H, Hishikawa T, Sekigawa I, Hashimoto H, Yamamoto N, Maruyama N. Sequence analysis of human endogenous retrovirus clone 4-1 in systemic lupus erythematosus. *Autoimmunity*. 2000;3(1): 15-21.
82. Ogasawara H, Okada M, Kaneko H, Hishikawa T, Sekigawa I, Hashimoto H. Possible role of DNA hypomethylation in the induction of SLE: Relationship to the transcription of human endogenous retroviruses. *Clinical and Experimental Rheumatology*. 2003;21(6):733-738.
83. Garry RF, Fermin CD, Hart DJ, Alexander SS, Donehower LA, Luo-Zhang H. Detection of a human intracisternal A-type retroviral particle antigenically related to HIV. *Science*. 1990;250:1127-1129.
84. Brookes SM, Pandolfino YA, Mitchell TJ, Venables PJ, Shattles WG, Clark DA, et al. The immune response to an expression of cross-reactive retroviral GAG sequences in autoimmune disease. *British Journal of Rheumatology*. 1992;31(11):735-742.
85. Hishikawa T, Ogasawara H, Kaneko H, Shirasawa T, Matsuura Y, Sekigawa I, et al. Detection of antibodies to a recombinant GAG protein derived from human endogenous retrovirus clone 4-1 in autoimmune diseases. *Viral Immunology*. 1997;10(3):137-147.
86. Lan MS, Mason A, Coutant R, Chen QY, Vargas A, Rao J, et al. HERVK10s and immune mediated (type 1) diabetes. *Cell*. 1998;95:1(2):14-16.
87. Somoza N, Vargas F, Roura-Mir C, Vives-Pi M, Fernandez-Figueras MT, Ariza A, et al. Pancreas in recent onset insulin-dependent diabetes mellitus: Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. *The Journal of Immunology*. 1994;153:1360-1377.
88. Conrad B, Weidmann E, Trucco G, Rudert WA, Behboo R, Ricordi C, et al. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. *Nature*. 1994;371:351-355.
89. Luppi P, Zanone MM, Hyoty H, Rudert WA, Haluszczak C, Alexander AM, et al. Restricted TCR V beta gene expression and enterovirus infection in type I diabetes: A pilot study. *Diabetologia*. 2000;43:1484-1497.
90. Stauffer Y, Marguerat S, Meylan F, Ucla C, Sutkowski N, Huber B, et al. Interferon-alpha-induced endogenous superantigen: A model linking environment and autoimmunity. *Immunity*. 2001;15:591-601.
91. Marguerat S, Wang WY, Todd JA, Conrad B. Association of human endogenous retrovirus K-18 polymorphisms with type 1 diabetes. *Diabetes*. 2004;53(3):852-854.
92. Mason MJ, Speake C, Gersuk VH, Nguyen Q-A, O'Brien KK, Odegard JM, et al. Low HERV-K (C4) copy number is associated with type 1 Diabetes. *Diabetes*. 2014; 63:1789-1795.
93. Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. *Cell*. 1997;90:303-313.
94. Iversen OJ. Isolation of virus-particles in urine from a psoriatic patient. *Acta Pathologica Microbiologica Et Immunologica Scandinavica*. 1983; 91B(1-6):407-412.
95. Dalen AB, Hellgren L, Iversen OJ, Vincent J. A virus-like particle associated with psoriasis. *Acta Pathologica Microbiologica Et Immunologica Scandinavica*. 1983; 91B(1-6):221-229.

96. Mole's J-P, Tesniere A, Guilhou J-J. A new endogenous retroviral sequence is expressed in skin of patients with psoriasis. *British Journal of Dermatology*. 2005; 153(1): 83-89.
97. Babcock M, Pavlicek A, Spiteri E, Kashork CD, Ioshikhes I, Shaffer LG, et al. Shuffling of genes within low-copy repeats on 22q11 (LCR22) by *Alu*-mediated recombination events during evolution. *Genome Research*. 2003;13:2519-2532.
98. Power C, Imaizumi K, Mallet F, Warren KG, Antony JM, Ellestad KK, et al. The human endogenous retrovirus envelope glycoprotein, syncytin-1, regulates neuroinflammation and its receptor expression in multiple sclerosis: A role for endoplasmic reticulum chaperones in astrocytes. *The Journal of Immunology*. 2007;179:1210-1224.
99. Perron H, Lang A. The human endogenous retrovirus links between genes an environment in multiple sclerosis and in multifactorial diseases associating neuro inflammation. *Clinical Reviews in Allergy and Immunology*. 2010;39:51-61.
100. Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, et al. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: A first-in-humans randomized clinical study. *Clinical Therapy*. 2012;34:2268-2278.
101. Mameli G, Poddighe L, Mei A, Uleri E, Sotgiu S, Serra C, et al. Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: Inference for multiple sclerosis. *PLoS ONE*. 2012;7:e44991.
102. Schmitt K, Richter C, Backes C, Meese E, Ruprecht K, Mayer J. Comprehensive analysis of human endogenous retrovirus group HERV-W locus transcription in multiple sclerosis brain lesions by high throughput amplicon sequencing. *Journal of Virology*. 2013;87:13837-13852.
103. Tai A, O'Reilly E, Alroy K, Simon K, Munger K, Huber B, et al. Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis. *Multiple Sclerosis*. 2008;14:1175-1180.
104. Ruprecht K, Gronen F, Sauter M, Best B, Rieckmann P, Mueller-Lantzsch N. Lack of immune responses against multiple sclerosis-associated retrovirus/human endogenous retrovirus W in patients with multiple sclerosis. *Journal of Neurovirology*. 2008;14:143-151.
105. Yolken R. Viruses and schizophrenia: A focus on herpes simplex virus. *Herpes*. 2004;11(suppl. 2):83A-88A.
106. Shastry BS. Schizophrenia: A genetic perspective (review). *International Journal of Molecular Medicine*. 2002;9:207-212.
107. Singh SK. Endogenous retroviruses: Suspects in the disease world. *Future Microbiology*. 2007;2:269-275.
108. Rees E, Kirov G, Sanders A, Walters JTR, Chambert KD, Shi J, et al. Evidence that duplications of 22q11.2 protect against schizophrenia. *Molecular Psychiatry*. 2014;19: 37-40.
109. Karlsson H, Bachmann S, Schröder J, McArthur J, Torrey EF, Yolken RH. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. *Proceedings of the National Academy of Sciences of the United States of America*. 2001;98(8):4634-4639.
110. Karlsson H, Schroder J, Bachmann S, Bottmer C, Yolken RH. HERVW- related RNA detected in plasma from individuals with recent-onset schizophrenia or schizoaffective disorder. *Molecular Psychiatry*. 2004;9(1):12-13.
111. Yolken RH, Karlsson H, Yee F, Johnston-Wilson NL, Torrey EF. Endogenous retroviruses and schizophrenia. *Brain Research Reviews*. 2000;31(2-3):193-199.
112. Frank O, Giehl M, Zheng C, Hehlmann R, Leib-Mosch C, Seifarth W. Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorders. *Journal of Virology*. 2005;79(17):10890-10901.
113. Weis S, Llenos IC, Sabunciyani S, Dulay JR, Isler L, Yolken R, et al. Reduced expression of human endogenous retrovirus (HERV)-W GAG protein in the cingulate gyrus and hippocampus in schizophrenia, bipolar disorder, and depression. *Journal of Neural Transmission*. 2007;114(5):645-655.
114. Lin M, Pedrosa E, Shah A, Hrabovsky A, Maqbool S, Zheng D, et al. RNA-seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. *PLoS ONE*. 2011;6(9):e23356.

115. Dickerson F, Rubalcaba E, Viscidi R, Yang S, Stallings C, Sullens A, et al. Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia. *Schizophrenia Research*. 2008;104(1-3):121-126.
116. Perron H, Mekaoui L, Bernard C, Veas F, Stefas I, Leboyer M. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. *Biological Psychiatry*. 2008;64(12):1019-1023.
117. Yao Y, Schroder J, Nellaker C, Bottmer C, Bachmann S, Yolken RH, et al. Elevated levels of human endogenous retrovirus-W transcripts in blood cells from patients with first episode schizophrenia. *Genes Brain and Behavior*. 2008;7(1):103-112.
118. Huang W, Li S, Hu Y, Yu H, Luo F, Zhang Q, et al. Implication of the env gene of the human endogenous retrovirus W family in the expression of BDNF and DRD3 and development of recent-onset schizophrenia. *Schizophrenia Bulletin*. 2011;37(5):988-1000.
119. Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, et al. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. *Multiple Sclerosis*. 2012;18(12):1721-1736.
120. Perron H, Hamdani N, Faucard R, Lajnef M, Jamain S, Daban-Huard C, et al. Molecular characteristics of human endogenous retrovirus type-W in schizophrenia and bipolar disorder. *Translational Psychiatry*. 2012;2:e201.
121. Abrusan G. Somatic transposition in the brain has the potential to influence the biosynthesis of metabolites involved in Parkinson's disease and schizophrenia. *Biology Direct*. 2012;7:41.
122. Williams EL, Casanova MF, Switala AE, Hong L, Qiu M. Transposable elements occur more frequently in autism-risk genes: Implications for the role of genomic instability in autism. *Translational Neuroscience*. 2013;4:172-202.
123. Balestrieri E, Pitzianti M, Matteucci C, D'Agati E, Sorrentino R, Baratta A, et al. Human endogenous retroviruses and ADHD. *The World Journal of Biological Psychiatry*. 2014;15(6):499-504.
124. Rusiecki JA, Chen L, Srikantan V, Zhang L, Yan L, Polin ML, et al. DNA methylation in repetitive elements and post-traumatic stress disorder: A case-control study of US military service members. *Epigenomics*. 2012;4(1):29-40.
125. Coufal NG, Garcia-Perez JL, Peng GE, Marchetto MC, Muotri AR, Mu Y, et al. Ataxia telangiectasia mutated (ATM) modulates long interspersed element-1 (L1) retrotransposition in human neural stem cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2011;108(51):20382-20387.
126. Cartault F, Munier P, Benko E, Desguerre I, Hanein S, Boddaert N, et al. Mutation in a primate-conserved retrotransposon reveals a noncoding RNA as a mediator of infantile encephalopathy. *Proceedings of the National Academy of Sciences of the United States of America*. 2012;109(13):4980-4985.
127. Schinke M, Izumo S. Deconstructing DiGeorge syndrome. *Nature Genetics*. 2001;27:238-240.
128. Belancio VP, Hedges DJ, Deininger P. Mammalian non-LTR retrotransposons: For better or worse, in sickness and in health. *Genome Research*. 2008;18:343-358.
129. Wimmer K, Callens T, Wernstedt A, Messiaen L. The NF1 gene contains hotspots for L1 endonuclease-dependent de novo insertion. *PLoS Genetics*. 2011;7:1-11.
130. Muratani K, Hada T, Yamamoto Y, et al. Inactivation of the cholinesterase gene by Alu insertion: Possible mechanism for human gene transposition. *Proceedings of the National Academy of Sciences of the United States of America*. 1991;88(24):11315-11319.
131. Hutchinson GB, Andrew SE, McDonald H, et al. An *Alu* element retroposition in two families with Huntington disease defines a new active *Alu* subfamily. *Nucleic Acids Research*. 1993;21(15):3379-3383.
132. Varon R, Gooding R, Steglich C, Marns L, Tang H, Angelicheva D, et al. Partial deficiency of the C-terminal-domain phosphatase of RNA polymerase II is associated with congenital cataracts facial dysmorphism neuropathy syndrome. *Nature Genetics*. 2003;35(2):185-189.
133. Tappino B, Regis S, Corsolini F, Filocamo M. An *Alu* insertion in compound heterozygosity with a microduplication in GNPTAB gene underlies Mucopolidosis II. *Molecular Genetics and Metabolism*. 2008;93:129-133.

134. Machado PM, Brandao RD, Cavaco BM, Eugenio J, Bento S, Nave M, Rodrigues P, et al. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. *Journal of Clinical Oncology*. 2007;25:2027-2034.
135. Schollen E, Keldermans L, Foulquier F, Briones P, Chabas A, Sanchez-Valverde F, et al. Characterization of two unusual truncating PMM2 mutations in two CDG-Ia patients. *Molecular Genetics and Metabolism*. 2007;90:408-413.
136. Udaka T, Okamoto N, Aramaki M, Torii C, Kosaki R, Hosokai N, et al. An Alu retrotransposition-mediated deletion of CHD7 in a patient with CHARGE syndrome. *American Journal of Medical Genetics*. 2007;143:721-726.
137. Chen J, Rattner A, Nathans J. Effects of L1 retrotransposon insertion on transcript processing, localization, and accumulation: Lessons from the retinal degeneration 7 mouse and implications for the genomic ecology of L1 elements. *Human Molecular Genetics*. 2006;15:2146-2156.
138. Chen JM, Masson E, Macek JM, Ragueneas O, Piskackova T, Fercot B, et al. Detection of two Alu insertions in the CFTR gene. *Journal of Cystic Fibrosis*. 2008;7:37-43.
139. Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, Yu C, Mori K, Oda T, et al. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. *Nature*. 2011;478:127-131.
140. Ostertag EM, Kazazian HH. Biology of mammalian L1 retrotransposons. *Annual Review of Genetics*. 2001;a35:501-538.
141. Mine´ M, Chen JM, Brivet M, Desguerre I, Marchant D, de Lonlay P, et al. A large genomic deletion in the PDHX gene caused by the retrotranspositional insertion of a full-length LINE-1 element. *Human Mutation*. 2007;28:137-142.
142. Kazazian HH, Wong C, Youssoufian H, Scott AF, Phillips DG, Antonarakis SE. Haemophilia a resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man. *Nature*. 1988;332(6160):164-166.
143. Choi J, Matsui KF, Sugimoto K, Suzuki H, Maeda Y, Yoshida Y, et al. Study of azoospermia factor-a deletion caused by homologous recombination between the human endogenous retroviral elements and population specific alleles in Japanese infertile males. *Fertility and Sterility*. 2008; 89:1177-1182.
144. Sun C, Skaletsky H, Rozen S, Gromoll J, Nieschlag E, Oates R, et al. Deletion of azoospermia factor a (AZFa) region of human Y chromosome caused by recombination between HERV15 proviruses. *Human Molecular Genetics*. 2000;9:2291-2296.
145. EPIgenie. Epigenetic Drug Therapies on the Rise; 2007.
146. Christian SL, Robinson WP, Huang B, Mutirangura A, Line MR, Nakao M, et al. Molecular characterization of two proximal deletion breakpoint regions in both Prader-Willi and Angelman syndrome patients. *American Journal of Human Genetics*. 1995;57:40-48.
147. Kiyosawa H, Chance PF. Primate origin of the CMT1A-REP repeat and analysis of a putative transposon-associated recombinational hotspot. *Human Molecular Genetics*. 1996;5:745-753.
148. Peedicayil J. Epigenetic therapy. A new development in pharmacology. *Indian Journal of Medical Research*. 2006; 123:17-24.

© 2016 Pandita and Pandita; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<http://sciencedomain.org/review-history/12908>